ECO Animal Health gets marketing authorisation for Aivlosin in Philippines

ECO Animal Health Group announced on Tuesday that its subsidiary, ECO Animal Health Limited, has received a marketing authorisation from the Animal Feeds, Veterinary Drugs and Biologics Control Division of the Bureau of Animal Industry of the Department of Agriculture in the Republic of the Philippines for the use of Aivlosin 625 mg/g water soluble granules in chickens laying eggs for human consumption.

The AIM-traded firm said the approval would allow it to start selling Aivlosin in the Philippines for the medication of drinking water for the treatment of infections caused by mycoplasma in poultry laying eggs for human consumption, with a zero-day drug withdrawal period for eggs.

ECO said it has begun the process of submitting the EU-approved Aivlosin regulatory files for the treatment of layers in numerous other key egg producing markets.

Aivlosin, ECO’s patented antimicrobial, was used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric diseases in poultry and pigs, its board explained.

“The Philippines is the fourth most important egg producing country in Southeast Asia and is ranked seventeenth globally for commercial layers,” said ECO Animal Health chairman Peter Lawrence.

“This latest approval demonstrates ECO’s continued progress towards becoming a major force in the international market for veterinary pharmaceutical products for livestock.”